TY - JOUR
T1 - Short and long term effects of antihypertensive therapy in the diabetic rat
AU - Anderson, S.
AU - Rennke, H. G.
AU - Garcia, D. L.
AU - Brenner, B. M.
N1 - Funding Information:
Portions of these studies were presented at the 21st Annual Meeting of the American Society of Nephrology, Dec. 3988, and published in abstract form (Kidney mt 35:422, 1989). These studies were supported by grants from the National Institutes of Health (AM 35930 and DK 30410) and from the Squibb Institute for Medical Research. D.L.G. was the recipient of a Research Fellowship Award from the National Kidney Foundation/Burroughs Wellcome Foundation. We are grateful to L.E. Clarey, S.J. Downes, K.J. Sandquist, and J.L. Troy for technical assistance.
PY - 1989
Y1 - 1989
N2 - To compare the impact of differing antihypertensive regimens on the development of renal injury, studies were performed in three groups of moderately hyperglycemic diabetic rats, and one group of non-diabetic control (C) rats. One diabetic group (DM) received no therapy except insulin. The remaining diabetic group received insulin and either the angiotensin I converting enzyme inhibitor captopril (CAP), or triple therapy (TRX) with reserpine, hydralazine and hydrochlorothiazide. CAP and TRX modestly and comparably lowered blood pressure. At 6 to 10 weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (Q(A)) and the glomerular capillary hydraulic pressure (P̄(GC)). In both DM/CAP and DM/TRX rats, blood pressure reduction was associated with selective normalization of P̄(GC), without change in SNGFR or Q(A). In long-term (70 weeks) studies, DM rats exhibited progressive albuminuria and marked glomerular sclerosis. CAP limited albuminuria and injury to values even lower than those in C rats, whereas TRX served only to delay, but not to prevent, the increase in albuminuria. TRX reduced glomerular sclerosis, but was less effective than CAP. At 70 weeks, CAP and TRX still reduced systemic blood pressure; P̄(GC) remained at normal levels with CAP but was no longer controlled with TRX. These results confirm the clinical observation that antihypertensive therapy slows diabetic glomerulopathy, but also suggest that CAP affords superior long-term protection as compared to the other antihypertensive drug regimen studied.
AB - To compare the impact of differing antihypertensive regimens on the development of renal injury, studies were performed in three groups of moderately hyperglycemic diabetic rats, and one group of non-diabetic control (C) rats. One diabetic group (DM) received no therapy except insulin. The remaining diabetic group received insulin and either the angiotensin I converting enzyme inhibitor captopril (CAP), or triple therapy (TRX) with reserpine, hydralazine and hydrochlorothiazide. CAP and TRX modestly and comparably lowered blood pressure. At 6 to 10 weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (Q(A)) and the glomerular capillary hydraulic pressure (P̄(GC)). In both DM/CAP and DM/TRX rats, blood pressure reduction was associated with selective normalization of P̄(GC), without change in SNGFR or Q(A). In long-term (70 weeks) studies, DM rats exhibited progressive albuminuria and marked glomerular sclerosis. CAP limited albuminuria and injury to values even lower than those in C rats, whereas TRX served only to delay, but not to prevent, the increase in albuminuria. TRX reduced glomerular sclerosis, but was less effective than CAP. At 70 weeks, CAP and TRX still reduced systemic blood pressure; P̄(GC) remained at normal levels with CAP but was no longer controlled with TRX. These results confirm the clinical observation that antihypertensive therapy slows diabetic glomerulopathy, but also suggest that CAP affords superior long-term protection as compared to the other antihypertensive drug regimen studied.
UR - http://www.scopus.com/inward/record.url?scp=0024429326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024429326&partnerID=8YFLogxK
U2 - 10.1038/ki.1989.227
DO - 10.1038/ki.1989.227
M3 - Article
C2 - 2681929
AN - SCOPUS:0024429326
SN - 0085-2538
VL - 36
SP - 526
EP - 536
JO - Kidney International
JF - Kidney International
IS - 4
ER -